TDC
CLVS

Thompson Davis & Co’s Clovis Oncology, Inc. CLVS Stock Holding History

Thompson Davis & Co’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-125
Closed -$5K – 1235
2016
Q3 		$5K Hold
125
– – 0.01% 850
2016
Q2 		$2K Buy
+125
New +$1.83K ﹤0.01% 981

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Thompson Davis & Co's CLVS Position: Q4 2016 in Review

Thompson Davis & Co sold out of Clovis Oncology, Inc. (CLVS) in Q4 2016, closing a stake of 125 shares — an estimated $5K sold.

Thompson Davis & Co first reported a position in CLVS in Q2 2016 and held it in 2 quarters. The position peaked at $5K in Q3 2016. 167 funds tracked by Wall St. Rank hold CLVS as of Q4 2016.

  • Thompson Davis & Co reported no remaining Clovis Oncology, Inc. position as of Q4 2016 after selling out during the quarter.
  • Thompson Davis & Co sold 125 Clovis Oncology, Inc. shares in Q4 2016, an estimated $5K.
  • Thompson Davis & Co first reported a position in Clovis Oncology, Inc. in Q2 2016 and held it in 2 quarters.
  • Thompson Davis & Co's Clovis Oncology, Inc. position peaked at $5K in Q3 2016.
  • 167 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2016.

Based on Thompson Davis & Co's 13F filing for Q4 2016, filed 7 Feb 2017.